Do you feel very tired throughout the day? There’s a chance you’re suffering from sleep deficiency.

This copper-infused pillow will give you the best night's sleep and it's on sale for more than 50% off

ANN ARBOR, Mich. Researchers at the University of Michigans Michigan Medicine and three other medical centers were awarded a total of $7 million from the National Heart, Lung, and Blood Institute (NHBLI) to study convalescent plasma in reducing symptoms of COVID-19 in patients with mild cases, Michigan Medicine announced Thursday. The other medical centers awarded funding are the University of Pittsburgh, Medical University of South Carolina and Stanford Medicine. As part of NHBLIs initiative, the Clinical Trial of COVID-19 Convalescent Plasma of Outpatients (C3PO), the institute plans to study whether preventing a mild case from becoming severe can come from passive immunization. Convalescent plasma contains antibodies that can bind to the virus that causes COVID-19, neutralizing it. A press release from Michigan Medicine said convalescent plasma can be used as a treatment for hospital patients with severe to life-threatening COVID-19, which is the passive immunization.

ANN ARBOR, Mich. Researchers at the University of Michigans Michigan Medicine and three other medical centers were awarded a total of $7 million from the National Heart, Lung, and Blood Institute (NHBLI) to study convalescent plasma in reducing symptoms of COVID-19 in patients with mild cases, Michigan Medicine announced Thursday. ORIGINAL STORY: Michigan Medicine awarded funding for COVID-19 plasma therapy trialMost of the other studies are focused on people who are so sick that they need to be in the ICU, said Dr. Frederick Korley. He said convalescent plasma -- donated by survivors -- contains antibodies that can bind to COVID-19 and neutralize it. Our hope is that if we can get to the patient early enough then -- with convalescent plasma -- we can neutralize the virus before the virus does a lot of damage to the body, Korley said. The study will enroll ER patients that have mild COVID-19 symptoms, but a high-risk for developing severe complications.